Efficacy and safety of neoadjuvant treatment regimens for early resectable non-small cell lung cancer:a network Meta-analysis
Objective To investigate the efficacy and safety of neoadjuvant treatment regimens for early resectable non-small cell lung cancer.Methods PubMed,Embase,MEDLINE,Cochrane Library and other da-tabases were searched to include clinical trials related to neoadjuvant therapy.Data such as pathological com-plete response,event-free survival,and incidence of adverse events of various treatment regimens were extrac-ted,and network meta-analysis was performed using R4.3.2 software.Results A total of 10 randomized con-trolled trials involving 3 650 patients and five neoadjuvant treatment regimens were included.Neoadjuvant chemoinunotherapy significantly improved pathological complete response and event-free survival compared to neoadjuvant chemotherapy alone(relative risk/hazard ratio=7.18,0.60;95%CI 2.96-18.60,0.37-0.97).There was no significant difference in the incidence of Grade 3 or higher adverse events among the treatment regimens(P>0.05).Conclusion For patients with early resectable non-small cell lung cancer,neoadjuvant immunotherapy combined with chemotherapy can enhance pathological remission and survival benefits.However,the addition of adju-vant immunotherapy following neoadjuvant treatment does not show a significant difference in survival benefits.
国家科技期刊平台
NSTL
万方数据
